MMP2 and Obesity: The results showed that the combination therapy was significantly more effective than either gemcitabine or MMP-2/9 inhibitor treatment alone for both non-obesity- and obesity-associated diabetic pancreatic cancer, resulting in the smallest tumor volume and lowest number of metastases (Figure 5, all p<0.05).